NCT06921850

A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

A Multicenter, Open-Label Study to Assess The Pharmacokinetics And Safety of Bimekizumab in Pubertal Children And Adolescents With Moderate to Severe Hidradenitis Suppurativa

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: UCB Biopharma SRL · Industry
• Sex: All
• Age: 9 Years – 17 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)

Conditions

• Hidradenitis Suppurativa

Interventions

Type	Name	Description
DRUG	Bimekizumab	Bimekizumab will be administered at pre-specified timepoints.

Timeline

• Start date: 2025-04-07
• Primary completion: 2026-12-21
• Completion: 2029-03-06
• First posted: 2025-04-10
• Last updated: 2026-03-27

Locations

18 sites across 3 countries: United States, Germany, Poland

Regulatory

• FDA-regulated drug study